Synthesis and structure-activity relationships of pyridoxal-6-arylazo-5?-phosphate and phosphonate derivatives as P2 receptor antagonists
- 1 October 1998
- journal article
- research article
- Published by Wiley in Drug Development Research
Abstract
Novel analogs of the P2 receptor antagonist pyridoxal‐5′‐phosphate‐6‐phenylazo‐2′,4′‐disulfonate (PPADS) were synthesized. Modifications were made through functional group substitution on the sulfophenyl ring and at the phosphate moiety through the inclusion of phosphonates, demonstrating that a phosphate linkage is not required for P2 receptor antagonism. Substituted 6‐phenylazo and 6‐naphthylazo derivatives were also evaluated. Among the 6‐phenylazo derivatives, 5′‐methyl, ethyl, propyl, vinyl, and allyl phosphonates were included. The compounds were tested as antagonists at turkey erythrocyte and guinea‐pig taenia coli P2Y1 receptors, in guinea‐pig vas deferens and bladder P2X1 receptors, and in ion flux experiments by using recombinant rat P2X2 receptors expressed in Xenopus oocytes. Competitive binding assay at human P2X1 receptors in differentiated HL‐60 cell membranes was carried out by using [35S]ATP‐γ‐S. A 2′‐chloro‐5′‐sulfo analog of PPADS (C14H12O9N3ClPSNa), a vinyl phosphonate derivative (C15H12O11N3PS2Na3), and a naphthylazo derivative (C18H14O12N3PS2Na2), were particularly potent in binding to human P2X1 receptors. The potencies of phosphate derivatives at P2Y1 receptors were generally similar to PPADS itself, except for the p‐carboxyphenylazo phosphate derivative C15H13O8N3PNa and its m‐chloro analog C15H12O8N3ClPNa, which were selective for P2X vs. P2Y1 receptors. C15H12O8N3ClPNa was very potent at rat P2X2 receptors with an IC50 value of 0.82 μM. Among the phosphonate derivatives, [4‐formyl‐3‐hydroxy‐2‐methyl‐6‐(2‐chloro‐5‐sulfonylphenylazo)‐pyrid‐5‐yl]methylphosphonic acid (C14H12O8N3ClPSNa) showed high potency at P2Y1 receptors with an IC50 of 7.23 μM. The corresponding 2,5‐disulfonylphenyl derivative was nearly inactive at turkey erythrocyte P2Y1 receptors, whereas at recombinant P2X2 receptors had an IC50 value of 1.1 μM. An ethyl phosphonate derivative (C15H15O11N3PS2Na3), whereas inactive at turkey erythrocyte P2Y1 receptors, was particularly potent at recombinant P2X2 receptors. Drug Dev. Res. 45:52–66, 1998. Published 1998 Wiley‐Liss, Inc.Keywords
This publication has 35 references indexed in Scilit:
- A Pyridoxine Cyclic Phosphate and Its 6-Azoaryl Derivative Selectively Potentiate and Antagonize Activation of P2X1 ReceptorsJournal of Medicinal Chemistry, 1998
- Effects of extracellular pH on agonism and antagonism at a recombinant P2X2 receptorBritish Journal of Pharmacology, 1997
- Receptors responsive to extracellular pyrimidine nucleotidesTrends in Pharmacological Sciences, 1997
- IMPLICATION OF ATP RECEPTORS IN BRAIN FUNCTIONSProgress in Neurobiology, 1996
- Purinergic receptors: their role in nociception and primary afferent neurotransmissionCurrent Opinion in Neurobiology, 1996
- Structure activity relationships for derivatives of adenosine‐5′‐triphosphate as agonists at P2 purinoceptors: Heterogeneity within P2x and P2y subtypesDrug Development Research, 1994
- Purinoceptors: Are there families of P2X and P2Y purinoceptors?Pharmacology & Therapeutics, 1994
- Chemical synthesis of stereospecifically labeled pyridoxamine 5'-phosphateThe Journal of Organic Chemistry, 1991
- Pyridoxal phosphate. I. Phosphonic acid analogs of pyridoxal phosphate. Synthesis via Wittig reactions and enzymic evaluationJournal of Medicinal Chemistry, 1969
- Synthesis of vitamin b6 derivatives. II. 3‐Hydroxy‐4‐hydroxymethyl‐2‐methyl‐5‐pyridine acetic acid and related substancesJournal of Heterocyclic Chemistry, 1966